Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluzone® Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

NCT03497845
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VN, IN, dk/BANG, gf/WA, bhg/QL, AS03 adjuvant, MF59 adjuvant
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

NCT01258595
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
5
States / cities
Idaho Falls, Idaho • Columbia, Maryland • Ellicott City, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

NCT02207413
View directory record Official record
Conditions
Influenza
Interventions
Influsplit Tetra™ vaccine produced by investigational process (IP), Influsplit Tetra™ vaccine produced by licensed process (LP)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 49 Years
Enrollment
1,886 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Wichita, Kansas • Rochester, New York • Warwick, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines

NCT00197288
View directory record Official record
Conditions
Influenza
Interventions
Influenza
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,847 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
15
States / cities
Clearwater, Florida • Evansville, Indiana • Baltimore, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 23, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

NCT07192458
View directory record Official record
Conditions
Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions
Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genetic and Environmental Factors in the Response to Influenza Vaccination

NCT03088904
View directory record Official record
Conditions
Influenza, Healthy
Interventions
FluMist® Quadrivalent, Fluzone® Quadrivalent vaccine
Biological
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 49 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Influenza Virus Vaccines in Children and Adults

NCT00988143
View directory record Official record
Conditions
Influenza
Interventions
2009-2010 Trivalent Influenza Virus Vaccine, 2008-2009 Trivalent Influenza Virus Vaccine, Quadrivalent Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Durham, North Carolina • Cincinnati, Ohio • Jefferson Hills, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

NCT01946438
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

NCT05514002
View directory record Official record
Conditions
Influenza, Human
Interventions
Fluzone Quadrivalent, Flublok Quadrivalent
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 64 Years
Enrollment
3,988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tallahassee, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

NCT02141581
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (IM), Fluzone® Intradermal (ID), 2011-2012 FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 34 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 23, 2026, 9:32 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

NCT02950688
View directory record Official record
Conditions
Influenza, Human
Interventions
Seasonal LAIV, Placebo, Wild-type A/California/2009-like Influenza Virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets

NCT03898986
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated influenza vaccine (LAIV4), Inactivated Influenza Vaccine (IIV4)
Biological
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 20 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

FLU-VACS Comparative Study in Adults

NCT00133523
View directory record Official record
Conditions
Influenza
Interventions
Cold-adapted live attenuated influenza virus vaccine, trivalent, Placebo, Trivalent inactivated influenza vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
2,349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
6
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • Livonia, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 23, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

NCT05947071
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047
View directory record Official record
Conditions
Diphtheria, Polio, Pertussis
Interventions
DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
36
States / cities
Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Glendale, Arizona • San Diego, California • Vista, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 23, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Defense Protein Impact On Respiratory Immune Outcomes

NCT07431840
View directory record Official record
Conditions
Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions
Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo
Dietary Supplement
Lead sponsor
Quantec Ltd
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

NCT01825200
View directory record Official record
Conditions
Influenza
Interventions
Flublok, Afluria
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
2,640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
14
States / cities
Tucson, Arizona • Coral Gables, Florida • Savannah, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 23, 2026, 9:32 AM EDT
Suspended Phase 3 Interventional

Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

NCT00828100
View directory record Official record
Conditions
Influenza
Interventions
fluID Rapid Influenza Test, BinaxNOW® Influenza A & B
Device
Lead sponsor
Nanogen, Inc.
Industry
Eligibility
Not listed
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Shreveport, Louisiana • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

NCT00380211
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
6
States / cities
Miami, Florida • Lenexa, Kansas • Binghamton, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 23, 2026, 9:32 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Durability of Vaccine Responses

NCT05801978
View directory record Official record
Conditions
Vaccine Response
Interventions
Live Attenuated Yellow Fever 17D Vaccine, Quadrivalent seasonal influenza vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 23, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

NCT00258830
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®: Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 23, 2026, 9:32 AM EDT